Matthew Rossen
Director/Board Member bij GARDINER HEALTHCARE ACQUISITIONS CORP.
Profiel
Matthew Rossen is an Independent Director at Gardiner Healthcare Acquisitions Corp.
and a Vice President-Marketing at Tarsus Pharmaceuticals, Inc. He was a Senior Director-Business Development at Jazz Pharmaceuticals, Inc. from 2010 to 2019 and a Senior Manager-Commercial Development at Pfizer Inc. from 2001 to 2010.
He was also an Independent Director at Chardan Healthcare Acquisition Corp.
from 2018 to 2019 and an Independent Director at Chardan Healthcare Acquisition 2 Corp.
He holds an undergraduate degree from The University of Colorado and an MBA degree from The Leonard N Stern School of Business.
Actieve functies van Matthew Rossen
| Bedrijven | Functie | Begin |
|---|---|---|
| GARDINER HEALTHCARE ACQUISITIONS CORP. | Director/Board Member | 01-10-2021 |
| TARSUS PHARMACEUTICALS, INC. | Sales & Marketing | - |
Eerdere bekende functies van Matthew Rossen
| Bedrijven | Functie | Einde |
|---|---|---|
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Sales & Marketing | 01-05-2021 |
| CHARDAN HEALTHCARE ACQUISITION CORP | Director/Board Member | 01-10-2019 |
Jazz Pharmaceuticals, Inc.
 Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | 01-04-2019 |
| PFIZER, INC. | Corporate Officer/Principal | 01-07-2010 |
| RENOVACOR, INC. | Director/Board Member | - |
Opleiding van Matthew Rossen
| The University of Colorado | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| TARSUS PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | Health Technology |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Health Technology |
Chardan Healthcare Acquisition Corp.
 Chardan Healthcare Acquisition Corp. Financial ConglomeratesFinance Chardan Healthcare Acquisition Corp. is a blank check company, which engages in seeking and acquiring one or more growth businesses. It focuses on businesses that have their primary operations located in North America in the healthcare industry. The company was founded on November 1 , 2017 and is headquartered in New York, NY. | Finance |
Chardan Healthcare Acquisition 2 Corp.
 Chardan Healthcare Acquisition 2 Corp. Financial ConglomeratesFinance Chardan Healthcare Acquisition 2 Corp. operates as a blank check company, which engages in the acquisition of healthcare company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on December 19, 2018 and is headquartered in New York, NY. | Finance |
Gardiner Healthcare Acquisitions Corp.
 Gardiner Healthcare Acquisitions Corp. Financial ConglomeratesFinance Gardiner Healthcare Acquisitions Corp. is a blank check company, which engages in merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination. The company was founded on March 25, 2021 and is headquartered in Shaker Heights, OH. | Finance |
